What are the recommended treatment and post‑exposure prophylaxis regimens for Cercopithecine herpesvirus 1 (monkey‑B virus) infection, including dosing adjustments for renal impairment?

Cercopithecine herpesvirus 1 (Monkey‑B virus): Treatment and Post‑Exposure Prophylaxis

Bold recommendation sentence at top per instruction Immediately start high‑dose intravenous ganciclovir for suspected or confirmed human B‑virus disease, and give prompt antiviral post‑exposure prophylaxis (PEP) after high‑risk macaque exposures, because delayed or absent therapy carries high mortality and severe neurologic morbidity 1, 2.

1) Post‑Exposure Prophylaxis (PEP) Algorithm (goal: prevent fatal encephalomyelitis; prioritize mortality/QoL)

• Immediate wound/mucosa care (time‑critical)
  • Copious washing/scrubbing with soap/water for ≥15 minutes; povidone–iodine to skin if available. Do not delay this step for anything 1.
• Risk stratify exposure (initiate PEP within hours if moderate/high risk)
  • High‑risk: deep bites/scratches from macaques, needlestick with macaque tissues/CSF/lesion material, mucosal splash with macaque secretions, delayed/inadequate wound care, exposure to ill macaque with oral/genital lesions. Strongly recommend PEP 1, 3.
  • Moderate‑risk: superficial percutaneous injury with potentially infectious material, brief mucosal exposure; consider PEP based on clinical judgment and exposure details 3.
  • Low‑risk: intact skin contamination promptly washed, contact with urine/feces only; PEP not recommended 3.
• PEP antiviral regimens (choose one; start ASAP, ideally within hours)
  • Oral valacyclovir 1 g three times daily for 14 days 1.
  • Oral acyclovir 800 mg five times daily for 14 days if valacyclovir unavailable 1.
  • If topical therapy is being considered at the inoculation site (adjunct, not a substitute): experimental animal data suggest topical cidofovir may be more effective than ganciclovir when begun within 8 hours; human data are lacking—do not rely on topical therapy alone 4.
• Monitoring during PEP
  • Educate on early symptoms (fever, headache, paresthesia at site, neurologic deficits); if symptoms develop, hospitalize immediately and switch to IV treatment (see below) 1.

Renal impairment dose adjustments for PEP (to prevent nephrotoxicity while preserving efficacy; target adherence/QoL):

• Valacyclovir (CrCl 30–49: 1 g q12h; 10–29: 1 g q24h; <10 or hemodialysis: 500 mg q24h, dose after HD). If local protocol not available, substitute acyclovir with renal‑adjusted dosing below.
• Acyclovir oral (from HIV OI guideline table as best available dosing source):
  • Severe renal dysfunction (CrCl <10 mL/min): 200 mg every 12 h (scale up toward 800 mg schedule as renal function allows); give after hemodialysis on HD days 5.

Common pitfalls and how to avoid:

• Waiting for laboratory confirmation before PEP—do not wait; PEP is time‑critical 1, 3.
• Inadequate wound decontamination—immediate, prolonged irrigation reduces inoculum and likely improves survival 1.
• Under‑treating high‑risk exposures—use the decision‑tool approach to standardize and avoid missed PEP 3.

2) Suspected or Confirmed B‑Virus Disease (Treatment)

• Hospitalize and start IV therapy immediately (high mortality without treatment; neurologic morbidity among survivors is severe).
• First‑line antiviral (most recent/highest‑quality actionable guidance prioritizing outcomes):
  • IV ganciclovir 5 mg/kg every 12 h, transition to oral valganciclovir when clinically improved and CSF/virologic markers (if obtained) stabilize; continue for a prolonged course as guided by clinical response and expert consultation 1. Animal and in‑vitro data indicate greater activity of ganciclovir than acyclovir against B virus, supporting its use for established infection to reduce mortality and neurologic injury 2.
• Alternative if ganciclovir contraindicated/not available:
  • IV acyclovir high dose (e.g., 10 mg/kg every 8 h) recognizing inferior activity vs B virus; switch to ganciclovir as soon as feasible 1, 2.
• Adjunctive care
  • ICU monitoring if encephalitis suspected; early neurology/infectious diseases involvement.
  • Avoid corticosteroids unless needed for specific indications; no evidence they improve outcomes for B virus and they may impair viral control.

Renal impairment dose adjustments for treatment (minimize nephrotoxicity; preserve efficacy and QoL):

• Ganciclovir (use HIV OI renal dosing table as the highest‑quality accessible dosing standard):
  • CrCl 50–69: 2.5 mg/kg IV q24h; 25–49: 1.25 mg/kg IV q24h; 10–24: 0.625 mg/kg IV q24h; <10: 0.625 mg/kg IV three times weekly; hemodialysis: 0.625 mg/kg after each HD 5.
• Acyclovir IV (general encephalitis guidance + renal cautions):
  • Reduce dose/frequency according to renal function; ensure aggressive IV hydration and frequent creatinine monitoring to prevent crystalluria/obstructive nephropathy, which can occur in up to 20% after several days IV therapy; dose reduce in pre‑existing renal impairment 6.
• Practical renal safety steps
  • Pre‑ and intra‑treatment IV hydration, avoid concomitant nephrotoxins, monitor SCr and urine output daily; adjust doses promptly with changes in renal function 6.

Common pitfalls and how to avoid:

• Delayed switch to ganciclovir in established disease—ganciclovir is more active; prioritize it to improve survival and neurologic outcomes 2.
• Missing early neurologic signs—paresthesia near exposure site or radicular pain can precede encephalitis; escalate immediately to IV therapy 1.

3) Evidence notes and strength

• Guideline‑style consensus from CDC‑convened working group provides the foundational, most authoritative approach for prevention/treatment; it emphasizes urgent PEP after risk assessment and ganciclovir preference for established disease to reduce mortality 1.
• Animal/in‑vitro studies demonstrating superior anti‑B‑virus activity of ganciclovir vs acyclovir underpin the treatment choice for confirmed disease (mortality/QoL critical outcomes) 2.
• A contemporary decision tool standardizes PEP selection and safely reduces unnecessary antivirals, supporting better adherence and safety in real‑world practice 3.
• Topical cidofovir shows superior prophylactic efficacy in mice when started within 8 h, but human evidence is absent—do not replace systemic PEP with topical therapy 4.

4) Exactly what to do now (checklist)

• If exposure just occurred: decontaminate immediately; assess risk; start oral valacyclovir 1 g TID for 14 days (renal‑adjust as above) for moderate/high‑risk exposures; arrange follow‑up and symptom monitoring 1, 3.
• If symptomatic or high suspicion for disease: admit; start IV ganciclovir 5 mg/kg q12h now (renal‑adjust per CrCl), aggressive renal monitoring; involve ID/neurology; plan step‑down to oral valganciclovir when stable 1, 2.
• Document exposure, notify occupational health/public health as appropriate; ensure source macaque evaluation if feasible.

Caveats

• Do not delay antivirals for testing. Testing can be pursued in parallel but should not postpone PEP or IV therapy given the high mortality 1.
• Adjust all nucleoside analogs for renal function; prevent acyclovir‑related nephropathy with hydration and monitoring 6.